Gynecologic Cancers

The 2025 SGO meeting will feature readouts of potentially impactful trial data in ovarian cancer, cervical cancer, and other gynecologic malignancies.

Incorporating frailty evaluation into practice may alter clinical decision-making for preoperative planning and patient counseling for gynecologic surgery.

Barriers and gaps in treatment and care for patients diagnosed with gynecologic cancers were reported in a recent survey.

Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

Ginger J. Gardner, MD, FACOG, walked through the strides of gynecologic cancer research and emphasized the efforts that still need to be accomplished.

A new surgical option of uterine transposition may help preserve fertility for women who have cancers of the pelvic region.

Pluta Cancer Center clinicians discussed how to improve sexual health outcomes for patients diagnosed with gynecological cancer.

PAX8, a marker for aggressive disease in numerous cancer types, was more highly expressed in Black patients with uterine serous carcinoma.

Data support subcutaneous envafolimab plus lenvatinib as a promising new therapy option in advanced endometrial cancer.

The CARACO study shows that adding retroperitoneal lymphadenectomy to cytoreductive surgery did not improve survival in advanced ovarian cancer.

Learn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.

Approval of the self-collection solution may reduce barriers to sample collection and increase access to cervical cancer screening.

The CheckMate 358 trial assessed various doses of nivolumab with or without ipilimumab for recurrent or metastatic cervical cancer.

Developers will work with investigators of the phase 3 KEYNOTE-B21 trial to share their findings with the scientific community.

The FDA has set a Prescription Drug User Fee Act date of August 23, 2024, for dostarlimab in all types of primary advanced endometrial cancer.

Combining rintatolimod with pembrolizumab may confer a synergistic effect in patients with recurrent ovarian cancer.

Even when adjusting for prior taxane responses in patients with ovarian cancer, ixabepilone/bevacizumab appears to yield survival benefits in a phase 2 trial.

Findings from the phase 2 RAMP 201 trial highlight responses with avutometinib/defactinib in those with KRAS-mutated low-grade serous ovarian cancer and other patient subgroups.

Nab-Sirolimus appears to produce responses in patients with perivascular epithelioid sarcoma regardless of TSC1/TSC2 mutation status.

Ex vivo generation of CD3-positive, CD56-positive Natural Killer-Like (NKT) with CRX100 was successful in all 7 patients with ovarian cancer in a phase 1 trial.

Data from the DUO-E trial support potential new durvalumab-based treatment options for patients with advanced or recurrent endometrial cancer.

Data from the phase 3 LEAP-001 study support lenvatinib plus pembrolizumab as an active combination for endometrial cancer.

The use of ChatGPT may help to improve genetic counseling for patients with gynecologic cancer.

Treatment with simple hysterectomy reduces the incidence of urinary incontinence compared with radical hysterectomy in patients with low-risk cervical cancer.

Data from the phase 3 RUBY trial support the recommendation for dostarlimab plus chemotherapy for patients with advanced MSI-H/dMMR endometrial cancer.

Data from the phase 3 NRG-GY018 trial support the supplemental biologics license application for pembrolizumab plus chemotherapy as a treatment for those with primary advanced or recurrent endometrial cancer.

Tisotumab vedotin may become the first antibody drug conjugate to receive marketing authorization in the European Union as a treatment for those with cervical cancer.

Treatment with pembrolizumab plus chemotherapy with or without bevacizumab yields an overall survival improvement regardless of squamous or nonsquamous cervical cancer histology.

Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.

Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.